Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Invokana Canagliflozin Diabetes mellitus, type 2 List with criteria/condition Complete
Invokana Canagliflozin Diabetes Mellitus, Type 2 Withdrawn
Iressa Gefitinib Cancer, Lung , non-small cell Do not list Complete
Isentress Raltegravir HIV (treatment naïve) Do not list Complete
Isentress Raltegravir HIV List with clinical criteria and/or conditions Complete
Istodax Romidepsin Peripheral T-Cell Lymphoma Reimburse with clinical criteria and/or conditions Complete
Isturisa osilodrostat Endogenous Cushing’s syndrome Suspended
Izba travoprost ophthalmic solution Glaucoma and ocular hypertension Reimburse with clinical criteria and/or conditions Complete
Jakavi ruxolitinib Graft versus host disease Reimburse with clinical criteria and/or conditions Complete
Jakavi ruxolitinib Graft versus host disease Reimburse with clinical criteria and/or conditions Complete